Bioprocesssing Technology Institute, A*STAR (BTI), Institute of Molecular and Cell Biology, A*STAR (IMCB) and NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI) are organising a Joint Workshop on "Advancing Biopharmaceuticals R&D and Manufacturing through Synthetic Biology” on 17 May 2016.
The BTI-IMCB-SynCTI Workshop will bring together leading scientists from academia, and industry to discuss and identify critical issues and challenges related to synthetic biology approaches for biopharmaceuticals R&D and advanced manufacturing. BTI, IMCB and SynCTI will sign a memorandum of understanding, followed by a workshop with academic and industrial speakers to strengthen the link between the institutes and the industry towards the vision of advancing biopharmaceuticals development and manufacturing though synthetic biology. This collaboration will be a synergistic partnership between the two pioneer BMS research institutes of A*STAR with NUS SynCTI to innovate and advance cell factory-manufacturing and the development of biopharmaceuticals for the industry.
- Uttam SURANA, Research Director, Institute of Molecular and Cell Biology, A*STAR
- Bing LIM, Associate Vice President for Research Science, Merck Research Laboratories, Translational Medical Research Center, Merck Sharp and Dohme, Singapore
- Wen Shan YEW, Associate Professor, Department of Biochemistry, NUS, and Principal Investigator, NUS Synthetic Biology for Clinical and Technological Innovation
- Andrea CAMATTARI, Associate Staff Scientist, Bioprocessing Technology Institute, A*STAR
- Robin PHILP, Academic Market Specialist for South East Asia, Agilent Technologies
- Hua LING, Senior Research Fellow, Department of Biochemistry, NUS, and NUS Synthetic Biology for Clinical and Technological Innovation
- Yuansheng YANG, Staff Scientist, Bioprocessing Technology Institute, A*STAR
- Kengo FUKUI, General Manager, Chitose Bio Evolution
- In Young HWANG, Research Fellow, Department of Biochemistry, NUS and NUS Synthetic Biology for Clinical and Technological Innovation
- Jay YANG, Asia-Oceania Business Manager, Singer Instruments
- Dong Yup LEE, Assistant Professor, Department of Chemical and Biomolecular Engineering, NUS, and Senior Scientist, Bioprocessing Technology Institute, A*STAR
For more details, please click HERE.
Thank you for your interest. The registration is now closed.
The biomedical industry has been developed as the fourth pillar of Singapore's economy. An important aspect of this is biopharmaceutical R&D and manufacturing which includes the large-scale production of therapeutic proteins for treatment of human ailments. Eight of the top ten biopharmaceutical companies in the world have their manufacturing facilities in Singapore, and the industrial production of biopharmaceuticals rely on mammalian and microbial cell factories such as Chinese Hamster Ovary (CHO) cells, Escherichia coli and yeast systems. Concurrently, past efforts in biopharmaceutical R&D in Singapore gained traction in 2015, with finafloxacin from MerLion Pharma (a spin-off from IMCB) becoming the first novel drug from a Singapore company to achieve FDA approval, and ETC-159 from ETC and Duke-NUS going into Phase I clinical trial. Emerging advances in synthetic biology, with its associated tools and predictive information, will enhance scientists’ abilities to design and create new biopharmaceuticals, optimize cell factories and implement new approaches for the advanced manufacturing of biopharmaceuticals and the development of human biotherapeutics. These tools empower biological design, control and production processes to a level not previously achievable.
Bioprocesssing Technology Institute, A*STAR (BTI) and Institute of Molecular and Cell Biology, A*STAR (IMCB), have been the pivotal institutions in Singapore’s biomedical research even before the nation’s biomedical science (BMS) initiative from 2000. BTI focuses on bioprocess science and bioengineering research, while IMCB focus on both cutting-edge basic and translational biomedical research. These institutions played an important role in Singapore’s success in the expansion of the biologics industry, and were instrumental in catalysing Singapore’s transformation into an international hub for biomedical research, development & innovation.
NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI) was formally established in 2014 as the focal research program for Synthetic Biology at the National University of Singapore, with a vision to develop novel biological and biologically-based systems with advanced clinical and industrial applications. SynCTI operates as a highly interdisciplinary research core that integrates researchers from various fields and interacts closely with research programs within local and international organizations, to revolutionize the way we study and engineer biology, and to catalyse the creation of new knowledge and new sectors of industry.